天风证券7月31日发布研报称，给予威胜信息（688100.SH，最新价：34.1元）买入评级。评级理由主要 包括：1）海外本地化深耕，境外业务收入实现良好增长；2）在手订单充裕，经营质量持续稳健，现金 流良好；3）AI助力新业务快速增长，赋能智慧电力系统及数智城市；4）重视股东权益持续分红，回 购彰显公司信心。风险提示：新技术研发及新产品开发风险；市场竞争风险；海外业务发展不达预期； 项目交付进度不及预期等。 （文章来源：每日经济新闻） ...

2025年6月6日，华致酒行股价创下年内最高点22.58元。 中国经济网北京7月31日讯 华致酒行(300755.SZ)今日收报18.20元，跌幅3.04%。 天风证券股份有限公司研究员张潇倩、何富丽、唐家全5月28日发布研报《华致酒行(300755)： Q1主动调整业绩短期承压25年利润修复弹性可期》称，维持华致酒行"买入"评级。 ...

作者：金股通 截至7月31日收盘回顾，主力资金流入前20的股票分别为：三六零（11.33亿元）、易点天下（8.89亿 元）、用友网络（8.81亿元）、诺德股份（8.05亿元）、神州数码（7.60亿元）、天风证券（7.20亿 元）、长城军工（6.84亿元）、剑桥科技（6.81亿元）、拓维信息（6.16亿元）、寒武纪U（5.79亿 元）、利欧股份（5.47亿元）、XD工业富（5.43亿元）、浪潮信息（5.03亿元）、长盈精密（4.92亿 元）、川润股份（4.51亿元）、南兴股份（4.20亿元）、安科生物（4.03亿元）、农业银行（3.73亿 元）、昆仑万维（3.65亿元）、华胜天成（2.85亿元）。 本文源自：金融界 ...

Core Viewpoint - The article highlights the increasing regulatory scrutiny in the securities industry, particularly focusing on the issue of "flying orders," where employees sell financial products not issued or authorized by their firms, leading to administrative penalties and warnings for both individuals and their respective firms [1][2]. Group 1: Regulatory Actions - The Chongqing Securities Regulatory Bureau issued a warning to Liao Moulin from Tianfeng Securities for selling non-company products, resulting in a warning letter for both him and his department [1]. - Liao Moulin's actions occurred during his tenure at Tianfeng Securities from April 7, 2022, to October 31, 2023, and he is now employed at Southwest Securities [1]. - The Chongqing Securities Regulatory Bureau also penalized Tianfeng Securities' Chongqing Qinyun Road branch for failing to prevent compliance risks related to Liao's actions, leading to a warning letter for the branch as well [1]. Group 2: Industry Trends - "Flying orders" are a common issue in the securities industry, where employees sell unauthorized financial products, reflecting a lack of compliance and risk management within firms [2]. - Other instances of "flying orders" include a case in February where Bohai Securities was penalized for not detecting employees selling private placement products, indicating systemic compliance weaknesses [2]. - The Jiangxi Securities Regulatory Bureau noted that such unauthorized financial products are often marketed as "high yield" and "low risk," posing significant risks to investors and leading to potential disputes [2].

Group 1 - The brokerage sector experienced a significant pullback on July 31, with 49 brokerage stocks declining, except for Tianfeng Securities, and notable drops in Haitou Shares and Bank of China Securities exceeding 3% [1] - The A-share leading brokerage ETF (512000) saw its intraday price drop by approximately 2%, currently down 1.45%, falling below the 10-day moving average [1] - According to Yinhe Securities, the policy goals of "stabilizing growth and the stock market" and "boosting the capital market" will continue to guide the future direction of the sector, supported by a moderately loose liquidity environment and improved investor confidence [2][3] Group 2 - As of July 30, 2025, the PB valuation of the CSI All Share Securities Company Index tracked by the brokerage ETF (512000) is 1.57 times, which is at a relatively low level within the past decade, indicating a high safety margin for investment [3] - The brokerage ETF (512000) encompasses 49 listed brokerage stocks, with nearly 60% of its holdings concentrated in the top ten leading brokerages, while the remaining 40% includes smaller brokerages with high earnings elasticity [3]

天风证券7月31日发布研报称，给予泽璟制药（688266.SH，最新价：114.42元）买入评级。评级理由主 要包括：1）已实现三个重点品种商业化，重组人促甲状腺激素有望于近期上市；2）ZG006：全球首个 CD3/DLL3/DLL3三抗，潜在BIC分子；3）ZG005：宫颈癌临床试验数据亮眼，积极拓展多项适应症。 风险提示：尚未盈利的风险，业绩大幅下滑或亏损的风险，核心竞争力风险，经营风险。 （文章来源：每日经济新闻） ...

Core Viewpoint - Zai Jian Pharmaceutical is recognized as an excellent innovative pharmaceutical company with both sales growth and research achievements, receiving a "buy" rating from Tianfeng Securities [1] Group 1: Commercialization and Product Pipeline - Zai Jian Pharmaceutical has successfully commercialized three key products, including Tofacitinib, Recombinant Human Thrombin, and Gilteritinib, with a fourth product, Recombinant Human Thyroid-Stimulating Hormone, expected to be launched soon [2] - The company is advancing its ZG006 product, a CD3/DLL3/DLL3 tri-antibody, which is in Phase 2 clinical trials and may become the first of its kind to enter Phase 3 trials globally [3] Group 2: Clinical Trial Results - ZG005, a PD-1/TIGIT dual antibody, has shown promising results in cervical cancer trials, with an overall response rate (ORR) of 40.9% and a disease control rate (DCR) of 68.2% in patients who had not previously received immune checkpoint inhibitors [4] Group 3: Financial Forecasts - The company is projected to achieve revenues of 820 million, 1.201 billion, and 1.603 billion RMB from 2025 to 2027, with net profits expected to be -20 million, 121 million, and 282 million RMB respectively, maintaining a "buy" rating [5] - Recent institutional ratings indicate a strong buy sentiment, with eight institutions giving a buy rating and an average target price of 77.18 RMB over the past 90 days [6]

Core Insights - The article highlights the top 20 stocks with significant capital inflow as of July 31, with Tianfeng Securities leading at 787 million yuan [1] Group 1: Capital Inflow - Tianfeng Securities received an inflow of 787 million yuan [1] - Nord Shares followed with an inflow of 743 million yuan [1] - Yidian Tianxia attracted 700 million yuan in capital [1] - Yongyou Network saw an inflow of 679 million yuan [1] - 360 Technology had an inflow of 668 million yuan [1] - Cambridge Technology received 645 million yuan [1] - Inspur Information attracted 603 million yuan [1] - XD Industrial Wealth saw an inflow of 590 million yuan [1] - Leo Holdings received 566 million yuan [1] - Changying Precision attracted 514 million yuan [1] - Tianfu Communication saw an inflow of 432 million yuan [1] - Cambrian AI received 415 million yuan [1] - Great Wall Military Industry attracted 405 million yuan [1] - Nanxing Shares saw an inflow of 338 million yuan [1] - Kunlun Wanwei received 303 million yuan [1] - Zhongji Xuchuang attracted 299 million yuan [1] - Shenghong Technology saw an inflow of 294 million yuan [1] - Hengbao Shares received 292 million yuan [1] - BlueFocus Communication attracted 271 million yuan [1] - Jiechang Drive saw an inflow of 249 million yuan [1]

Core Viewpoint - The article highlights the performance of new IPOs in the A-share market from January to July 2025, indicating a significant increase in both the number of new listings and the total funds raised compared to the same period last year [1]. Group 1: IPO Performance - A total of 59 new companies were listed in the A-share market from January to July 2025, representing an 18.00% increase from 50 companies in the same period last year [1]. - The net fundraising amount for these 59 new listings reached 544.21 billion yuan, which is a 63.83% increase compared to 332.18 billion yuan in the previous year [1]. Group 2: Underwriting Institutions Ranking - 26 underwriting institutions participated in the IPOs of the 59 new companies, with a total of 60 deals due to dual appointments for some companies [2]. - The top three underwriting institutions by the number of deals are: - First: Guotai Junan with 7 deals - Second: Huatai United and CITIC Securities, each with 6 deals [2]. Group 3: Legal and Accounting Firms Ranking - 25 law firms provided legal services for the 59 new IPOs, with the top three being: - First: Shanghai Jintiancheng with 9 deals - Second: Beijing Zhonglun with 6 deals - Third: Guangdong Xinda with 4 deals [5]. - 15 accounting firms provided auditing services for the IPOs, with the top three being: - First: Rongcheng with 13 deals - Second: Lixin and Tianjian, each with 9 deals [5].

Core Viewpoint - The report from Tianfeng Securities indicates that the chemical industry, particularly segments with high loss levels, high industry concentration, high proportion of outdated capacity, and high operating rates, may serve as a breakthrough point for "anti-involution" in the chemical sector, achieving goals through the shortest path [1] Group 1: Industry Characteristics - Segments such as soda ash, spandex, dyes (including reactive and disperse dyes), coal chemicals (including DMF, caprolactam, octanol, urea, acetate, etc.), polyurethane (TDI, MDI), titanium dioxide, and organic silicon are highlighted as key areas of focus [1] - These segments meet at least two of the specified screening criteria, suggesting they are more likely to experience significant changes [1]